Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Vericel Shares Rise After Higher Q3 Results, Raised 2026 Revenue Outlook

Vericel Shares Rise After Higher Q3 Results, Raised 2026 Revenue Outlook

MT newswireMT newswire2026/11/05 14:12
10:12 AM EST, 11/05/2026 (MT Newswires) -- Vericel (VCEL) shares were up over 21% on Thursday after the company reported higher Q3 earnings and revenue compared with a year earlier and raised its 2026 revenue outlook. The company reported Q3 earnings of $0.27 per diluted share, up from $0.10 a year earlier. Analysts surveyed by FactSet expected $0.06. Revenue for the quarter ended Sept. 30 was $85.4 million, up from $67.5 million a year earlier. Analysts expected $77.9 million. The company raised its 2026 revenue guidance to $344 million to $346 million from its previous outlook of $330 million to $340 million. Analysts expect $336.3 million. Price: 55.32, Change: +9.84, Percent Change: +21.62
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss